Most people who land in pharma didn’t plan the route – they took the first offer and figured out the rest later. That works fine for a few years. It stops working once you’re ten years in and realize you’ve built breadth in the wrong direction, or depth in a corridor that’s shrinking. The professionals who build genuinely long careers in this industry pick a lane early, then move deliberately within it.
Pharma has three real career corridors, not one
Many job boards seem to imply that there’s just one pharma career path and each job is a different room in that same house.
The reality is that there are three distinct corridors that all get thrown under the same roof:
- Discovery and Clinical Research (the bench-to-bedside pipeline and all Phase I-IV trials)
- Regulatory Affairs and Compliance (the documentation, submission strategy, and compliance corridor)
- Medical Affairs and Commercial-Facing Science (the corridor where scientific credibility meets external communication)
Here’s what they all ask of you on day one:
Discovery and Clinical Research values technical depth, protocol design skill, and patience – because your one trial is going to run for years before anyone touches the results.
Regulatory Affairs and Compliance values documentation, submission strategy, and fluency in the GLP, GCP, and GMP frameworks along with the ICH guidelines that govern how a drug moves from lab to approval. It’s less glamorous than the other two, but it’s also one of the most recession-resistant tracks in the entire industry, because approvals still have to happen whether the broader market is hiring or not.
Medical Affairs and Commercial-Facing Science values technical depth, strong presentation skills, and the ability to represent the scientific voice of a company in rooms where credibility matters. This is where the Medical Science Liaison role sits, and it’s the corridor most people underestimate when they’re early in their careers.
Picking late is expensive. Someone who spends eight years in bench research and then decides they want a medical affairs role has to backfill years of KOL exposure and public-speaking reps that a deliberate early mover would already have. It’s not impossible to pivot late. It’s just slower and costs you leverage in salary negotiations.
Why the MSL role is the smartest bridge out of the bench
If you have a Ph.D. or clinical qualification and are looking to remain in a more scientific role without dedicating your entire career to a lab or clinic, then becoming a Medical Science Liaison is something to give some serious thought to. When companies look to hire an MSL, they are not looking for someone who can sell, but rather someone who can engage in a scientific discussion with their peers – would you be able to sit down with a clinician who has been in the field of oncology for twenty years and discuss trial data, mechanism of action, and the latest literature?
This dynamic requires a very different skill set from a sales environment. MSLs are responsible for KOL relationship management, translating often very complex trial data for internal teams, and representing the scientific face of the company in environments where it would not be appropriate to have a sales rep. For many scientists who miss the intellectual stimulation of research but are not keen on the idea of spending another ten years working at the bench, this role offers the best legal connection between where they are now and the business side of the industry. The recruitment process reflects this. MSL interviews will often involve a presentation or mock literature critique, rather than a behavioral competency interview. If you can present a dataset to a room of skeptical clinicians and hold your ground, you’re likely going to make the shortlist.
Time your moves around the drug development cycle
A single new drug reaching the market requires an investment of $2.6 billion and 10-15 years on average, and about 90% of drug candidates fail to reach the finish line (DiMasi et al., Journal of Health Economics). That’s valuable information for more than just tailoring your applications – pharma hiring is lumpy, and certain events within that long timeline create steep demand for roles.
Positive Phase III results in a late-stage pipeline cause a cluster of firms to rush to build out their medical-affairs teams. Regulatory submission experts are in high demand right before regulatory windows, so every firm is competing to hire the same people. Virtually all companies compete to hire the relatively small number of qualified MSLs when a new product is introduced.
You can use the timeline of a firm’s anticipated pipeline events to predict when they’ll need to staff up for a specific role. If you’re monitoring for a job post to open, you’ll be competing with every job seeker who also reads the same post. If you’re monitoring for an interesting job post to open and making contact in advance, you’re giving yourself an advantage. And that’s easy to do – you’re already paying attention to the business.
Credentials that actually move the needle
An MBA in general doesn’t help much with a scientific-track pharma career. Recruiters here want proof based on the role, not generalized business skills.
For regulatory affairs, the RAC (Regulatory Affairs Certification) shows you grasp submission strategy at a level an MBA doesn’t get to. For clinical operations, the CCRP (Certified Clinical Research Professional) serves a similar function. For medical affairs and MSL-track candidates, the equivalent isn’t a cert – it’s peer-reviewed publications, conference presentations, or contributions to trial protocols. In these roles, there’s no additional credential that substitutes for making it clear that you contribute when talking to clinicians.
This is where a lot of career planning goes wrong. People collect broad credentials assuming breadth reads as strength. In pharma’s scientific tracks, depth in the right lane reads as strength. Breadth reads as indecision.
Move deliberately across employers in your first decade
Professionals who reach senior matrixed leadership positions rarely spent their formative ten years in one company. They left approximately every two or three years, and they left on purpose – CRO to biotech, biotech to big pharma, sponsor-side to CRO and back.
A Parexel or IQVIA is a smart first employer even if you want a sponsor-side career in the end. Therapeutic switching and client-switching are easier to achieve in this kind of role than in any role inside one large company’s structure. Startup and biotech roles are also smart early employers because they force you to wear several hats at once, which accelerates skill breadth faster than a mature pharma environment ever will.
The path that generally doesn’t work is the one where you stay in one comfortable role for eight years and expect a senior title to materialize. Seniority in this industry is earned through demonstrated range across the drug lifecycle, not tenure in a single function.
How MSL and medical affairs roles actually get filled
Here’s something most career guides don’t include: a large proportion of MSL and senior medical affairs roles aren’t ever listed on a jobs page. No business wants to be overwhelmed with dozens of applications for a position that necessitates the scientific standing of a peer and the previous KOL relationship-building experience of a pro, so they engage niche channels instead.
This is where medical science liaison recruitment through specialist pharma search firms becomes relevant, as they assess candidates on presentation of science, expertise in the therapeutic space, and previous interaction with KOLs, rather than running CVs through an applicant tracking system. Firms that operate in this space invite the talented individuals they expect to place for a coffee long before any jobs open up, meaning that when the spot debuts it’s candidates who remembered the recruiter’s name that get a call.
If you want to go down this path, you should treat specialist headhunters as a network contact, not as a job-finding tool. Keep them up to date. Drop them a line when you work on a new publication or give a public talk. Shoot them an email when you change your specialism. The unlisted roles are where the vast majority of the market is, and you only get to play in that space by having actively stayed in a recruiter’s mind before a search is launched.
Pick a therapeutic area and stay there
It’s hard out there for a generalist in field-medical hiring. If you’re choosing between becoming deeply familiar with oncology, immunology, neurology, or rare disease over a broad but shallow background across five therapeutic areas, pick the former. You will consistently lose out to the specialists, and they have a point. Reps in a division of a large pharma company cover one or two therapeutic areas. Some entire field-medical teams cover only one.
KOLs in a given specialty know each other, attend the same conferences, and expect the MSL sitting across from them to speak their specific clinical language fluently. A generalist can fake competency for one meeting. A specialist builds a reputation across dozens of meetings over years, and that reputation is what makes the role sustainable long-term rather than a two-year stopover.
Pick your therapeutic area early if you can, and resist the urge to diversify just because a job posting looks appealing. Depth compounds. Breadth across therapeutic areas mostly doesn’t.
Geography still matters, even in a remote-friendly world
Field med roles designed around KOL visits don’t work remotely. You have to physically be there for site visits, advisory boards, conferences, and that hasn’t changed even as other corporate functions went remote.
Leadership-density roles are still in four or five places in the world – Boston and Cambridge, the Bay, Basel, Singapore. If your long-term goal is a senior seat, proximity to one of these clusters at some point in your career is not optional – it’s where the decision-makers and your peer network actually live. You don’t have to move there permanently, but be honest with yourself about whether a fully remote strategy will get you where you want to go in fifteen years.
Build a portfolio of credibility, not a list of job titles
Job titles don’t always reflect the actual level of responsibility an individual may hold, as this can vary significantly between companies. A better indicator of a candidate’s qualifications is their portfolio; real, measurable contributions to publications, trial protocols, regulatory submissions, conference presentations, and Key Opinion Leader (KOL) relationships.
Start building your portfolio early by co-authoring where possible. If the opportunity arises, present at conferences such as DIA or ISPE – these conferences aren’t just a chance to pad your resume, they provide the visibility among your peers that will eventually lead to recruiter interest. Keep a running list of your actual contributions in projects, not just your responsibilities.
For senior candidates, get proof of your “matrixed influence”. Particularly in roles within Medical Affairs, hiring managers will be looking for evidence that you can lead and gain consensus from a cross-functional team (clinical, legal, marketing) even though you don’t manage or direct any members of that team. This can’t be done without developing a particular skill set around influence and negotiation, so get your real examples laid out rather than assuming it’s implied with your title.
Watch the disruption coming for the next decade
AI-driven target discovery, generative AI in medical writing, and decentralized trial models are already changing how work gets done inside pharma. Professionals who ignore these shifts risk finding their specific skill set less relevant in ten years, even if their credentials look fine on paper today.
This doesn’t mean abandoning deep scientific specialization. It means staying current enough that you’re not blindsided when a task you’ve built a career around gets automated or restructured. The MSLs and regulatory specialists who’ll still be indispensable in 2035 are the ones layering new digital fluency onto their existing scientific depth now, not the ones waiting to see how it plays out.
Run several strategies at once
The candidates who move fastest into medical affairs and MSL roles aren’t waiting for one perfect opening. They’re running contract work, biotech lateral moves, secondments, and direct relationships with specialist recruiters all at the same time.
Pharma careers reward people who treat the job search as an ongoing relationship-building exercise rather than a series of discrete applications. Build the scientific portfolio. Pick the therapeutic area. Stay visible at the conferences that matter. And keep the specialist recruiters in your corner long before you need them, because by the time a role is posted publicly, the best candidates have often already been found.
